It is printed in the A4 size.To the laboratory site

 - Clinical Medicine (Core Departments) - Internal Medicine
Cardiovascular Medicine
The Cardiovascular Medicine at Kyoto University, aims at elucidating the cause of the cardiovascular disease and therapeutic measures for it and making their assessment by use of both basic and clinical research approach. We strongly hope that young doctors become balanced clinicians who weight not only cardiovascular emergency medicine but also the preventive medical care. We are also training them to be able to send information about our researches to the world. We have resolved to make significant contributions to the tomorrow’s cardiovascular medicine in Japan.

  Takeshi Kimura
Research and Education
■Basic Research
・We conduct highly original research in the cardiovascular field using novel strategies of molecular biology, physiology and molecular genetics. Both of the clinical and the basic research are essential for the progress of the cardiovascular medicine. Therefore, our basic research group keeps in close contact with clinical research.
・We try to expand the possibilities of ourselves. Participation of young researchers or those from different fields provide us more extensive studies. We welcome new colleagues who are interested in our research field.
・Our aim is to elucidate the pathophysiology of cardiovascular diseases and develop novel methods of diagnosis and therapeutic strategies. In addition, we perform translational research with wide clinical application.
■Clinical Research
Members of the Department of Cardiovascular Medicine at Kyoto University are continuously contributing to evidence-based health care through clinical researches and education in the fields of cardiovascular medicine. Currently, we conduct over ten clinical studies including five multicenter randomized controlled trials in collaboration with major foremost hospitals in Japan. The major targets of our clinical research include ischemic heart disease, heart failure, arrhythmia, peripheral artery disease, aortic disease, hypertension, and cardiac rehabilitation.

In detail, please visit our department’s homepage. URL:

Cardiovascular Medicine
Professor Takeshi Kimura

(Industry-Academia Collaboration)
Eiichiro Nishi

Tetsuo Shioi, Koh Ono

Yoshiki Yui, Chiharu Kishimoto,
Satoshi Shizuta, Takeru Makiyama, Neiko Ozasa
(Industry-Academia Collaboration)
Yoshinori Hiraoka, Mikiko Ohno, Takahiro Horie, Masao Imai
Naritatsu Saito, Junichi Tazaki
TEL +81-75-751-3185
FAX +81-75-751-3289
A Murine Model of Acute Myocardial Infarction
Hypertensive Heart Failure in Dahl Salt-Sensitive Rat
Cardiac Catheterization Laboratory
Biostatics Seminar for Graduate Students and young doctors
Staff of Department of Cardiovascular Medicine
Recent Publications
1. Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, Shiode N, Namura M, Sone T, Oshima S, Nishikawa H, Hiasa Y, Hayashi Y, Nobuyoshi M, Mitudo K; j-Cypher Registry Investigators. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation. 2012;125:584-91.
2. Imai M, Kadota K, Goto T, Fujii S, Yamamoto H, Fuku Y, Hosogi S, Hirono A, Tanaka H, Tada T, Morimoto T, Shiomi H, Kozuma K, Inoue K, Suzuki N, Kimura T, Mitsudo K. Incidence, risk factors, and clinical sequelae of angiographic peri-stent contrast staining after sirolimus-eluting stent implantation. Circulation. 2011;123:2382-91.
3. Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, Kinoshita M, Kuwabara Y, Marusawa H, Iwanaga Y, Hasegawa K, Yokode M, Kimura T, Kita T. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci U S A. 2010;107:17321-6.
4. Kimura T, Morimoto T, Kozuma K, Honda Y, Kume T, Aizawa T, Mitsudo K, Miyazaki S, Yamaguchi T, Hiyoshi E, Nishimura E, Isshiki T; RESTART Investigators. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation. 2010;122:52-61.
5. Ohno M, Hiraoka Y, Matsuoka T, Tomimoto H, Takao K, Miyakawa T, Oshima N, Kiyonari H, Kimura T, Kita T, Nishi E. Nardilysin regulates axonal maturation and myelination in the central and peripheral nervous system. Nat Neurosci. 2009;12:1506-13.
6. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, Nishikawa H, Hiasa Y, Muramatsu T, Meguro T, Inoue N, Honda H, Hayashi Y, Miyazaki S, Oshima S, Honda T, Shiode N, Namura M, Sone T, Nobuyoshi M, Kita T, Mitsudo K; j-Cypher Registry Investigators. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation. 2009;119:987-95.
7. Inuzuka Y, Okuda J, Kawashima T, Kato T, Niizuma S, Tamaki Y, Iwanaga Y, Yoshida Y, Kosugi R, Watanabe-Maeda K, Machida Y, Tsuji S, Aburatani H, Izumi T, Kita T, Shioi T. Suppression of phosphoinositide 3-kinase prevents cardiac aging in mice. Circulation. 2009;120:1695-703.